Literature DB >> 1321008

Phase II study of high-dose aclarubicin in previously treated patients with small-cell lung cancer.

P B Jensen1, S K Larsen, I Stilbo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1321008     DOI： 10.1007/bf00686316

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


× No keyword cloud information.
  11 in total

1.  Phase II evaluation of aclarubicin in lung cancer: a Southeastern Cancer Study Group Trial.

Authors:  B S Kramer; R Birch; J P Gockerman; A Greco; K Prestridge
Journal:  Cancer Treat Rep       Date:  1986-06

2.  Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, Denmark.

Authors:  O P Hansen; J Pedersen-Bjergaard; J Ellegaard; H Brincker; A M Boesen; B E Christensen; A Drivsholm; E Hippe; H Jans; K B Jensen
Journal:  Leukemia       Date:  1991-06       Impact factor: 11.528

3.  Phase II study of aclarubicin and diaziquone in the treatment of advanced small cell bronchogenic carcinoma (EST 4581): an Eastern Cooperative Oncology Group Study.

Authors:  M D Abeloff; D M Finkelstein; A Y Chang; F J Camacho; R H Creech; D S Ettinger
Journal:  Cancer Treat Rep       Date:  1985-04

Review 4.  Pharmacodynamic aspects of aclarubicin with special reference to daunorubicin and doxorubicin.

Authors:  T Skovsgaard
Journal:  Eur J Haematol Suppl       Date:  1987

5.  New anthracycline antibiotic aclacinomycin A: experimental studies and correlations with clinical trials.

Authors:  T Oki; T Takeuchi; S Oka; H Umezawa
Journal:  Recent Results Cancer Res       Date:  1981

6.  Phase I--II evaluation of a new anthracycline antibiotic, aclacinomycin A, in adults with refractory leukemia.

Authors:  R P Warrell; Z A Arlin; S J Kempin; C W Young
Journal:  Cancer Treat Rep       Date:  1982-08

7.  Intermittent high-dose aclarubicin in patients with advanced cancer: a phase I study with special reference to cardiac toxicity.

Authors:  K Aabo; S A Mortensen; T Skovsgaard; E Gymoese
Journal:  Cancer Treat Rep       Date:  1983-03

8.  Phase I-II study of aclarubicin for treatment of acute myeloid leukemia.

Authors:  D Machover; J Gastiaburu; M Delgado; E Goldschmidt; R Hulhoven; J L Misset; F de Vassal; H Tapiero; P Ribaud; L Schwarzenberg
Journal:  Cancer Treat Rep       Date:  1984-06

9.  Aclarubicin in the treatment of acute nonlymphocytic leukemia refractory to treatment with daunorubicin and cytarabine: a phase II trial.

Authors:  J Pedersen-Bjergaard; H Brincker; J Ellegaard; A Drivsholm; L Freund; K B Jensen; M K Jensen; N I Nissen
Journal:  Cancer Treat Rep       Date:  1984-10

10.  In vitro evaluation of the potential of aclarubicin in the treatment of small cell carcinoma of the lung (SCCL).

Authors:  P B Jensen; L Vindeløv; H Roed; E J Demant; M Sehested; T Skovsgaard; H H Hansen
Journal:  Br J Cancer       Date:  1989-12       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.